Results 11 to 20 of about 3,124 (157)

Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection-General and Special Populations. [PDF]

Aliment Pharmacol Ther
Current first‐line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD.
Mak LY, Hu TH, Yap DYH.
europepmc   +2 more sources

Compound adsorption device in pathogen reduction technology removes multiple drugs from plasma components. [PDF]

Transfusion
Abstract Background Blood donor eligibility policies may exclude individuals based on medication use, but the donor health questionnaire may not reliably capture all prescriptions. This study evaluates the capacity of the compound adsorption device (CAD) within the INTERCEPT Blood System Pathogen Reduction Technology (PRT) for plasma to remove ...
Greenwall B, Reeder K, Anani WQ.
europepmc   +2 more sources

Evaluation of pharmacokinetic interactions between long-acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084. [PDF]

J Int AIDS Soc
Abstract Introduction HPTN 084 found that long‐acting cabotegravir (CAB‐LA) was well‐tolerated and significantly reduced the risk of HIV acquisition in women compared to tenofovir disoproxil fumarate/emtricitabine (F/TDF). During the blinded phase of the trial, participants were required to use an effective method of contraception, including an ...
Marzinke MA, Hanscom B, Haines D, Scarsi KK, Agyei Y, Piwowar-Manning E, Hendrix CW, Gollings R, Rose S, Mathew C, Panchia R, Spooner E, Singh N, Bock P, Rinehart AR, Ford SL, Rooney JF, Soto-Torres L, Cohen MS, Hosseinipour MC, Delany-Moretlwe S, HPTN 084 Study Team.   +21 more
europepmc   +2 more sources

Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea. [PDF]

Br J Clin Pharmacol
Aims Demographics and kidney function contribute to variability in lamivudine and tenofovir drug concentrations. The aim was to assess, for the first time, the pharmacokinetic variability of lamivudine and tenofovir in Papua New Guinean (PNG) HIV/AIDS patients.
Andriguetti NB, Barratt DT, Tucci J, Pumuye P, Somogyi AA.   +4 more
europepmc   +2 more sources

Giresun’daki Fındık Fabrikalarının Etkinlik Analizi: Malmquist - TFV Endeksi Uygulaması [PDF]

Adnan Menderes Üniversitesi Sosyal Bilimler Enstitüsü Dergisi, 2014
Bu calismanin amaci 2006–2012 donemi icin Giresun’daki findik fabrikalarinin performanslarini incelemektir. Belirlenen donemler icin her bir fabrikanin Toplam Faktor Verimliligindeki degisim, Malmquist- Toplam Faktor Verimliligi Endeksi yontemi kullanilarak incelenmistir.
DOĞAN, Hatice, BULUT, Yetkin
openaire   +3 more sources

Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT Oral preexposure prophylaxis (PrEP) has been approved for prophylaxis of HIV-1 transmission but is associated with high costs and issues of adherence. Protection from anal transmission of HIV using topical microbicides and methods congruent with sexual behavior offers the promise of improved adherence.
Peng, Xiao, Sanjeev, Gumber, Mark A, Marzinke, Abhijit A, Date, Thuy, Hoang, Justin, Hanes, Laura M, Ensign, Lin, Wang, Lisa, Rohan, Edward J, Fuchs, Craig, Hendrix, Francois, Villinger   +11 more
openaire   +2 more sources

Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya

Frontiers in Reproductive Health, 2023
IntroductionGlobally, many young women face the overlapping burden of HIV infection and unintended pregnancy. Protection against both may benefit from safe and effective multipurpose prevention technologies.MethodsHealthy women ages 18–34 years, not ...
Nelly R. Mugo, Nelly R. Mugo, Victor Mudhune, Renee Heffron, Renee Heffron, Katherine K. Thomas, Eleanor McLellan-Lemal, Betty Njoroge, Sue Peacock, Siobhán M. O’Connor, Beatrice Nyagol, Eunice Ouma, Renee Ridzon, Jeffrey Wiener, Nina Isoherranen, David W. Erikson, Louise A. Ouattara, Nazita Yousefieh, Terry A. Jacot, Richard E. Haaland, Susan A. Morrison, Harald S. Haugen, Andrea R. Thurman, Shannon A. Allen, Jared M. Baeten, Jared M. Baeten, Jared M. Baeten, Taraz Samandari, Taraz Samandari, Gustavo F. Doncel   +29 more
doaj   +1 more source

Oral pre-exposure prophylaxis initiation, continuation and adherence among pregnant and postpartum women receiving antenatal and postnatal care: a systematic review. [PDF]

J Int AIDS Soc
Abstract Introduction In 2023, one‐fourth of new HIV acquisitions in children globally resulted from vertical transmission following incident HIV during pregnancy or breastfeeding. Oral pre‐exposure prophylaxis (PrEP) with tenofovir disoproxil and emtricitabine is safe and effective in pregnancy and postpartum, with long‐acting options emerging ...
Rotsaert A, Essack Z, Bosman S, Davey DJ, Hensen B.   +4 more
europepmc   +2 more sources

K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism. [PDF]

PLoS ONE, 2011
HIV-1 carrying the "Q151M complex" reverse transcriptase (RT) mutations (A62V/V75I/F77L/F116Y/Q151M, or Q151Mc) is resistant to many FDA-approved nucleoside RT inhibitors (NRTIs), but has been considered susceptible to tenofovir disoproxil fumarate (TFV ...
Atsuko Hachiya, Eiichi N Kodama, Matthew M Schuckmann, Karen A Kirby, Eleftherios Michailidis, Yasuko Sakagami, Shinichi Oka, Kamalendra Singh, Stefan G Sarafianos   +8 more
doaj   +1 more source

A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate. [PDF]

PLoS ONE, 2014
This Phase 1, randomized, two-site (United States), double-blind, placebo-controlled study enrolled 18 sexually abstinent men and women. All received a single 300-mg dose of oral tenofovir disoproxil fumarate (TDF) and were then randomized 2:1 to receive
Kuo-Hsiung Yang, Craig Hendrix, Namandje Bumpus, Julie Elliott, Karen Tanner, Christine Mauck, Ross Cranston, Ian McGowan, Nicola Richardson-Harman, Peter A Anton, Angela D M Kashuba   +10 more
doaj   +1 more source